Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 504 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia, Schizoaffective Disorder Clear all
Terminated Phase 2 Interventional Results available

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Bronx Psychiatric Center
Government
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Buffalo, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Development of a Mobile System for Self-management of Schizophrenia (SOS)

NCT01969500
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Mobile Application, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Not applicable Interventional Results available

Models of Auditory Hallucination

NCT04210557
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Health Promotion and Fitness for Younger and Older Adults With SMI

NCT02090335
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
In SHAPE, Fitness Club Membership
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses

NCT00494650
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive behavioral therapy (CBT), Brief PTSD treatment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Monmouth Junction, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness

NCT02334228
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Major Depressive Disorder
Interventions
In SHAPE Lifestyles, Health Club Membership and Education
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Concord, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder

NCT00316303
View directory record Official record
Conditions
HIV Infections, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression, Substance Abuse
Interventions
Twinrix, Enhanced treatment as usual
Drug · Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Get Moving and Get Well - Pilot Study

NCT01884025
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression, Post Traumatic Stress Disorder
Interventions
Get Moving and Get Well, Health and Humor Class
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Cognitive Training and Enhanced Supported Employment in Schizophrenia

NCT00339170
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer-Based Cognitive Enhancement Training Program, Work Therapy Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
20 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)

NCT03873337
View directory record Official record
Conditions
Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia, Schizoaffective Disorder
Interventions
Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
Behavioral · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 4 Interventional

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Sibutramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
16
States / cities
El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCT00320671
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

NCT05321602
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions
LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Not applicable Interventional

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
sham stimulation, transcranial magnetic stimulation
Device
Lead sponsor
Deepak K. Sarpal, M.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Remediation of Working Memory in Schizophrenia

NCT00995553
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Skills
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness

NCT04011280
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Nicotine Dependence
Interventions
Varenicline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 4 Interventional

The Effects of Aripiprazole on Patients With Metabolic Syndrome

NCT00224822
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions
Aripiprazole
Drug
Lead sponsor
New Mexico VA Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Jul 23, 2026, 11:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2

NCT00135772
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 3 Interventional

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554
View directory record Official record
Conditions
Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions
Lumateperone 42 mg, Risperidone 2 mg
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Not applicable Interventional Results available

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results

NCT04548622
View directory record Official record
Conditions
Schizophrenia
Interventions
Magstim Rapid 2 system triggering Magstim Super Rapid system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 23, 2026, 11:41 PM EDT